Keros Therapeutics Authorizes Additional $5 Mln Share Repurchase Program
(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, on Monday announced that its board of directors has approved an additional $5 million share repurchase program.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.